We’ve created INOFEA from the desire to meet a critical need related to enzyme lack of stability and robustness: the possibility to provide enzymes with resistance to in vivo and process conditions, so that they could be fully deployed in the health industry.
Unlike other existing technologies, our innovative nanotechnology platform is capable of shielding sensitive enzymes and has positively demonstrated substantial benefits to customers in a number of health industry applications.
Meet us on EBF symposium (European Bioanalysis Forum) in Barcelona on Nov. 21 – 23, 2018.
INOFEA gladly invites Pharmaceutical companies and CROs to meet with us on the EBF symposium (European Bioanalysis Forum) in Barcelona on Nov. 21 – 23, 2018.
More than 500 people mainly from pharmaceutical companies and CROs meet in November in Barcelona to use this landmark event for bioanalytical discussions. The goal of bringing experts in the field of bioanalysis together is to exchange experiences, discuss scientific topics, talk about day to day procedures, business tools, technologies or regulatory themes and to learn about news in the many lectures provided by professionals.
INOFEA will have a booth during the EBC and we are looking forward to giving you all insights into our new enzyme-empowering technology, being particularly developed for protein analysis, showing many benefits in comparison to conventional enzymes.
The event takes place in the NH Collection Tower, Barcelona, Spain.
INOFEA will be represented by the CEO, Dr. Yves Dudal and CBO, Dr. Anne Timm.